Regulation of Monocyte Chemoattractant Protein-1 Through Angiotensin II Type 1 Receptor in Prostate Cancer
Regulation of Monocyte Chemoattractant Protein-1 Through Angiotensin II Type 1 Receptor in Prostate Cancer
复制标题
DOI：
10.1016/j.ajpath.2011.11.027
复制
发表时间：
2012-03-01
影响因子：
6
通讯作者：
Oya, Mototsugu
中科院分区：
文献类型：
--
作者：
Shirotake, Suguru;Miyajima, Akira;Oya, Mototsugu
单核细胞趋化蛋白-1（MCP-1/CCL 2）被报道促进肿瘤进展，并在高血压疾病中受肾素-血管紧张素系统调节。在这项研究中，我们研究了前列腺癌（CaP）患者MCP-1表达的临床结果和MCP-1通过血管紧张素II（AngII）1型受体（AT 1 R）在CaP中的调节。从138名CaP患者获得标本，并通过MCP-1和巨噬细胞的免疫染色进行分析。我们使用三种人前列腺癌细胞系：LNCaP、C4-2和C4- 2AT 6，研究了通过AT 1 R在体内和体外对MCP-1表达的调节。具有高Gleason评分（>= 7）和高病理分类（
Monocyte chemoattractant protein-1 (MCP-1/CCL2) is reported to contribute to tumor progression and is regulated by the renin-angiotensin system in hypertensive disease. In this study, we investigated the clinical outcome of MCP-1 expression in patients with prostate cancer (CaP) and the regulation of MCP-1 through angiotensin II (AngII) type 1 receptor (AT1R) in CaP. Specimens were obtained from 138 CaP patients and analyzed by immunostaining for both MCP-1 and macrophages. We investigated the regulation of MCP-1 expression through AT1R both in vivo and in vitro using three human prostate cancer cell lines: LNCaP, C4-2, and C4-2AT6. Specimens with a high Gleason score (>= 7) and a high pathological classification (